A Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive

NCT06524518 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

213

Enrollment

OTHER

Sponsor class

Conditions

DFS

Interventions

DRUG: Chemotherapy combined with immunization

Sponsor

Xuanwu Hospital, Beijing